At the intersection of health and the climate is an urgent crisis. This crisis affects health in ways that are wide-ranging, ...

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

Antimicrobial resistance (AMR) is an urgent global health crisis. AMR infections cause an estimated 1.3 million deaths globally every year, and this number is only projected to rise.

US drug pricing policies will have global impacts on innovation and access The knowledge generated through biomedical innovation is a public good. One person’s use does not reduce its availability to ...

In this report, we explore the status of access and uptake for NGS testing for lung cancer in Europe, develop the health economic case for NGS testing, and identify barriers and opportunities for ...

The purpose of this research is to identify the attributes to include in a value framework for orphan medicinal products (OMPs), determine their relative importance using a multi-criteria decision ...

Real-World Evidence (RWE) can provide decision-makers in the healthcare sector with insights into the functioning of health technologies outside of clinical trial settings. In this report, we focus on ...

Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this ...

Our Board of Trustees and advisory committees are essential to guiding our work, maintaining the quality and independence of our research programme and our publications, and ensuring we align with our ...

The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS ...

In this report, we propose a novel payment model that will incentivise broader value demonstration for diagnostics for antibiotics that could inform longer-term financing and reimbursement ...

In this report, we describe the design of a globally aligned, value-based, fully-delinked pull incentive, where payers provide manufacturers with a pre-specified subscription fee based on the value of ...